Advertisement

Screening for Lynch syndrome among patients with newly diagnosed endometrial cancer: a comprehensive review

Abstract

Lynch syndrome (LS) is an autosomal dominant condition characterized by an increased risk of hereditary colorectal, endometrial, ovarian, pancreatic, urinary tract, and gastric cancer.

It is estimated that around 5% of all endometrial cancer (EC) cases are due to an inherited predisposition, of which LS might be the most frequent. The lifetime risk of developing EC in women with LS ranges between 40% and 71% depending on the type of mutation. In many cases, this risk may even exceed their risk of developing colon cancer. Moreover, in 60% of these women, EC will be the first primary malignancy diagnosed and the sentinel diagnosis of the syndrome. Therefore, it is essential to identify which women with EC have LS in order to allow implementation of individualized screening and preventive strategies.

Tumori 2016; 102(6): 548 - 554

Article Type: REVIEW

DOI:10.5301/tj.5000385

Authors

Elena Aguirre, Begoña Graña, Miguel Boudet, Judith Balmaña

Article History

Disclosures

Financial support: None.
Conflict of interest: None.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Oncology, Hospital Arnau de Vilanova, Lleida - Spain
  • Department of Oncology, Complexo Hospitalario a Corula, Galicia - Spain
  • Department of Digestive, Hospital Arnau de Vilanova, Lleida - Spain
  • Department of Oncology, Hospital Vall D’Hebron, Barcelona - Spain

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.